NEWS
Institutional Subscription: Comprehensive Analyses to Enhance Your Global and Local Impact
New Feature: Compare Your Institution with the Previous Year
Find a Professional: Explore Experts Across 197 Disciplines in 220 Countries!
Find a Professional
Print Your Certificate
New! Young University / Institution Rankings 2025
New! Art & Humanities Rankings 2025
New! Social Sciences and Humanities Rankings 2025
Highly Cited Researchers 2025
AD
Scientific Index 2025
Scientist Rankings
University Rankings
Subject Rankings
Country Rankings
login
Login
person_add
Register
insights
H-Index Rankings
insights
i10 Productivity Rankings
format_list_numbered
Citation Rankings
subject
University Subject Rankings
school
Young Universities
format_list_numbered
Top 100 Scientists
format_quote
Top 100 Institutions
format_quote
Compare & Choose
local_fire_department
Country Reports
person
Find a Professional
Daniel Rea
University of Birmingham - Birmingham / United Kingdom
Others
AD Scientific Index ID: 4321694
Registration, Add Profile,
Premium Membership
Print Your Certificate
Ranking &
Analysis
Job
Experiences (0)
Education
Information (0)
Published Books (0)
Book Chapters (0)
Articles (0)
Presentations (0)
Lessons (0)
Projects (0)
Subject Leaders
Editorship, Referee &
Scientific Board (0 )
Patents /
Designs (0)
Academic Grants
& Awards (0)
Artistic
Activities (0)
Certificate / Course
/ Trainings (0)
Association &
Society Memberships (0)
Contact, Office
& Social Media
person_outline
Daniel Rea's MOST POPULAR ARTICLES
1-)
Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trialsEarly Breast Cancer Trialists\\\' Collaborative GroupThe Lancet 386 (10001), 1341-1352, 201510222015
2-)
aTTom: Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years in 6,953 women with early breast cancer.RG Gray, D Rea, K Handley, SJ Bowden, P Perry, HM Earl, CJ Poole, ...Journal of Clinical Oncology 31 (18_suppl), 5-5, 20135442013
3-)
Phase I pharmacokinetic and pharmacodynamic study of the oral mammalian target of rapamycin inhibitor everolimus in patients with advanced solid tumorsA O\\\'Donnell, S Faivre, HA Burris III, D Rea, V Papadimitrakopoulou, ...Journal of Clinical Oncology 26 (10), 1588-1595, 20085332008
4-)
Antibacterial prophylaxis after chemotherapy for solid tumors and lymphomasM Cullen, N Steven, L Billingham, C Gaunt, M Hastings, P Simmonds, ...New England Journal of Medicine 353 (10), 988-998, 20054862005
5-)
Adjuvant tamoxifen and exemestane in early breast cancer (TEAM): a randomised phase 3 trialCJH Van de Velde, D Rea, C Seynaeve, H Putter, A Hasenburg, ...The Lancet 377 (9762), 321-331, 20114832011
ARTICLES
Add your articles
We use cookies to personalize our website and offer you a better experience. If you accept cookies, we can offer you special services.
Cookie Policy
Accept